AR005945A1 - Composicion farmaceutica para la modulacion inmunitaria - Google Patents

Composicion farmaceutica para la modulacion inmunitaria

Info

Publication number
AR005945A1
AR005945A1 ARP970100701A ARP970100701A AR005945A1 AR 005945 A1 AR005945 A1 AR 005945A1 AR P970100701 A ARP970100701 A AR P970100701A AR P970100701 A ARP970100701 A AR P970100701A AR 005945 A1 AR005945 A1 AR 005945A1
Authority
AR
Argentina
Prior art keywords
peptide
pharmaceutical composition
adjuvant
cells
vaccine
Prior art date
Application number
ARP970100701A
Other languages
English (en)
Spanish (es)
Inventor
Walter Schmidt
Max Birnstel
Peter Steinlein
Michael Buschle
Tamas Schweighoffer
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27215945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR005945(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19607044A external-priority patent/DE19607044A1/de
Priority claimed from DE19638313A external-priority patent/DE19638313C2/de
Priority claimed from DE19648687A external-priority patent/DE19648687A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR005945A1 publication Critical patent/AR005945A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP970100701A 1996-02-24 1997-02-21 Composicion farmaceutica para la modulacion inmunitaria AR005945A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19607044A DE19607044A1 (de) 1996-02-24 1996-02-24 Tumorvakzine und Verfahren zu ihrer Herstellung
DE19638313A DE19638313C2 (de) 1996-09-19 1996-09-19 Pharmazeutische Zusammensetzung für die Immunmodulation
DE19648687A DE19648687A1 (de) 1996-11-25 1996-11-25 Pharmazeutische Zusammensetzung für die Immunmodulation

Publications (1)

Publication Number Publication Date
AR005945A1 true AR005945A1 (es) 1999-07-21

Family

ID=27215945

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970100701A AR005945A1 (es) 1996-02-24 1997-02-21 Composicion farmaceutica para la modulacion inmunitaria

Country Status (34)

Country Link
US (1) US7105162B1 (2)
EP (1) EP0881906B2 (2)
JP (1) JP4184433B2 (2)
KR (1) KR100457647B1 (2)
CN (1) CN1177610C (2)
AR (1) AR005945A1 (2)
AT (1) ATE274350T1 (2)
AU (1) AU722264B2 (2)
BG (1) BG63682B1 (2)
BR (1) BR9707694A (2)
CA (1) CA2243559C (2)
CO (1) CO4600681A1 (2)
CZ (1) CZ295396B6 (2)
DE (1) DE59711873D1 (2)
DK (1) DK0881906T4 (2)
EE (1) EE04481B1 (2)
ES (1) ES2225951T5 (2)
HR (1) HRP970100B1 (2)
HU (1) HU224410B1 (2)
ID (1) ID16038A (2)
IL (1) IL125361A (2)
MY (1) MY119276A (2)
NO (1) NO983850L (2)
NZ (1) NZ332020A (2)
PE (1) PE55398A1 (2)
PL (1) PL189413B1 (2)
PT (1) PT881906E (2)
RO (1) RO119344B1 (2)
RS (1) RS50101B (2)
SI (1) SI0881906T2 (2)
SK (1) SK284582B6 (2)
TR (1) TR199801649T2 (2)
TW (1) TW585774B (2)
WO (1) WO1997030721A1 (2)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
DE69936355T2 (de) * 1998-02-25 2008-02-21 The Government Of The United States, As Represented By The Secretary Of The Army Verwendung von Hautpenetrationsförderern und für die Zerstörung der oberen Hautschichten geeigneten Mitteln zur Erhöhung der transkutanen Immunantwort
AU765260B2 (en) * 1998-04-20 2003-09-11 Torrey Pines Institute For Molecular Studies Topical immunostimulation to induce langerhans cell migration
WO2000048630A1 (en) * 1999-02-17 2000-08-24 Csl Limited Immunogenic complexes and methods relating thereto
DE19909503A1 (de) * 1999-03-04 2000-09-07 Boehringer Ingelheim Int Tumorassoziiertes Antigen
US6809179B1 (en) 1999-08-04 2004-10-26 Boehringer Ingelheim International Gmbh Tumor-associated antigen (R11)
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) * 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
AT409762B (de) * 2000-04-13 2002-11-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung von zytokin sekretierenden zellen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
KR20020014459A (ko) * 2000-08-18 2002-02-25 서진호 양이온성 아미노산이 부가된 융합단백질 및 이를 이용한생물공정의 개선방법
JP2004519453A (ja) * 2001-01-05 2004-07-02 インターツェル・アクチェンゲゼルシャフト ポリカチオン性化合物の用途
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
WO2002053184A2 (en) * 2001-01-05 2002-07-11 Intercell Ag Uses for polycationic compounds as vaccine adjuvants
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
FR2824326B1 (fr) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
JP2005519035A (ja) * 2001-12-07 2005-06-30 インターツェル・アクチェンゲゼルシャフト 免疫促進性オリゴデオキシヌクレオチド
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
CA2484941A1 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
EP2402026A3 (en) 2002-09-13 2012-04-18 Intercell AG Method for isolating hepatitis C virus peptides
WO2004035618A2 (en) 2002-10-15 2004-04-29 Intercell Ag Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
SI1601770T1 (sl) 2003-03-04 2010-01-29 Intercell Ag Streptococcus pyogenes antigeni
ATE485056T1 (de) 2003-03-24 2010-11-15 Intercell Ag Verbesserte impfstoffe
DE602004024179D1 (de) 2003-03-31 2009-12-31 Intercell Ag Staphylococcus epidermidis antigene
EP2333114A1 (en) 2003-04-15 2011-06-15 Intercell AG S. pneumoniae antigens
EP2275435A3 (en) 2003-05-07 2011-08-31 Intercell AG Streptococcus agalactiae antigens I + II
EP2327720A1 (en) 2003-05-30 2011-06-01 Intercell AG Enterococcus antigens
CN1822856B (zh) 2003-07-11 2010-04-28 英特塞尔股份公司 Hcv疫苗
ATE381945T1 (de) 2004-03-12 2008-01-15 Intercell Ag Verfahren zur solubilisierung von peptid- mischungen
DE102004038134B4 (de) 2004-08-05 2013-07-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Multivalente Chelatoren zum Modifizieren und Organisieren von Zielmolekülen, Verfahren zu ihrer Herstellung sowie ihre Verwendung
US9573979B2 (en) 2004-09-24 2017-02-21 Susanne Modrow Modified VP1-capsid protein of parvovirus B19
US20090060875A1 (en) * 2004-10-29 2009-03-05 Intercell Ag HCV Vaccines for Chronic HCV Patients
EP1872793B1 (en) * 2005-04-20 2012-10-10 Mitsuru Akashi Polyamino acid for use as adjuvant
EP1887084A1 (en) 2006-08-10 2008-02-13 International Investment and Patents SA Plasmids with immunological action
AU2007295927A1 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
JP2008174490A (ja) * 2007-01-18 2008-07-31 Nitto Denko Corp 抗原性ペプチドを主成分とする薬剤
EP2489673A3 (en) 2007-05-02 2012-09-12 Intercell AG Klebsiella antigens
KR100748265B1 (ko) * 2007-06-15 2007-08-10 (주)성문엔지니어링 공동주택에 배선된 전선의 합선방지구조
EP2167530A2 (en) 2007-06-18 2010-03-31 Intercell AG Chlamydia antigens
EP2173376B1 (en) 2007-08-02 2015-03-25 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
WO2009120378A2 (en) * 2008-03-27 2009-10-01 Nestec S.A. Methods for increasing absorption of peptides, peptidomimetics, and other gastrointestinal transport protein substrates
US20110236470A1 (en) 2008-12-03 2011-09-29 Yaffa Mizrachi Nebenzahl GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
WO2010092176A2 (en) 2009-02-13 2010-08-19 Intercell Ag Nontypable haemophilus influenzae antigens
CN102740882A (zh) * 2009-08-27 2012-10-17 诺华有限公司 含有铝、寡核苷酸和聚阳离子的佐剂
CN102695501A (zh) 2009-11-09 2012-09-26 聚光灯技术合伙有限责任公司 碎裂水凝胶
EP2498763A4 (en) 2009-11-09 2015-10-07 Spotlight Technology Partners Llc HYDROGELE ON POLYSACCHARIDBASIS
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
CA2828068C (en) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
RU2478399C2 (ru) * 2011-06-16 2013-04-10 Государственное научное учреждение Всероссийский научно-исследовательский институт бруцеллеза и туберкулеза животных Российской академии сельскохозяйственных наук (ГНУ ВНИИБТЖ Россельхозакадемии) Способ получения специфического иммуномодулятора
US20140271723A1 (en) * 2013-03-15 2014-09-18 Saint Louis University Adjuvant compositions and methods of using thereof
RU2684911C2 (ru) 2014-10-07 2019-04-16 Ситлимик Инк. Пептид, полученный из hsp70, фармацевтическая композиция для лечения или профилактики рака, содержащая такой пептид, индуктор иммунного ответа и способ получения антиген-презентирующей клетки
SG10201912485PA (en) 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
KR101850417B1 (ko) * 2015-12-16 2018-04-20 주식회사 휴벳바이오 스쿠알렌을 포함하는 양친매성 폴리 아미노산 고분자 기반 백신 면역보조제 조성물
EP3431595A4 (en) * 2016-03-15 2019-11-20 Repertoire Genesis Incorporation MONITORING AND DIAGNOSIS FOR IMMUNOTHERAPY AND DESIGN FOR THERAPEUTICS
CN109890408A (zh) * 2016-05-27 2019-06-14 埃特彼塞斯公司 新表位疫苗组合物及其使用方法
AU2017342189B2 (en) 2016-10-11 2023-09-21 Nec Corporation Medicine
CN107469067B (zh) * 2017-09-05 2018-06-19 浙江大学 一种多肽及其改造体在制备免疫调节药物中的应用
MA52363A (fr) 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
CN110870912A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 亚甲蓝类染料作为疫苗佐剂的应用、包含该佐剂的疫苗及其应用
CN110870913A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 氨基酸类营养素作为疫苗佐剂的应用以及包含氨基酸营养素作为佐剂的疫苗
CN117860879A (zh) * 2024-01-10 2024-04-12 广州医科大学附属肿瘤医院 一种纳米疫苗递送系统及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1290141A (2) 1968-05-31 1972-09-20
US4847240A (en) * 1978-01-16 1989-07-11 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US4728639A (en) * 1982-07-27 1988-03-01 University Of Tennessee Research Corporation Type-specific opsonic antibodies evoked with a synthetic peptide of streptococcal M protein conjugated to polylysine without adjuvant
US6022544A (en) * 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US4956273A (en) * 1985-10-24 1990-09-11 Southwest Foundation For Biomedical Research Synthetic peptides and method of use for diagnosis and vaccination for AIDS and ARC
BE1000587A4 (fr) 1986-06-13 1989-02-14 Oncogen Coordinats et procedes en vue d'augmenter la proliferation des lymphocytes b.
DE346022T1 (de) * 1988-06-10 1990-05-23 Medical Research Council, London Peptidfragmente von hiv.
DE68927679T2 (de) * 1988-10-27 1997-06-26 Univ Minnesota Immunhilfsmittel aus Liposome enthaltend Lymphokin IL -2
EP0510054A1 (en) 1990-01-05 1992-10-28 United Biomedical, Inc. Hiv-1 core protein fragments
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
DK0636028T3 (da) 1992-04-03 2004-07-12 Univ California Selvorganiserende polynucleotidleveringssystem omfattende et amfipatisk kationisk peptid
ES2225824T3 (es) 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.
US5571711A (en) * 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5409703A (en) * 1993-06-24 1995-04-25 Carrington Laboratories, Inc. Dried hydrogel from hydrophilic-hygroscopic polymer
CZ5191U1 (cs) 1993-07-12 1996-09-12 Aliatros Medical, A.S. Farmaceutický prostředek pro imunomodulační a adjuvantní léčbu
JP2828391B2 (ja) * 1993-10-29 1998-11-25 東燃株式会社 オリゴ糖を表面に有するリポソーム
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
US6001809A (en) * 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
UY24367A1 (es) † 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju

Also Published As

Publication number Publication date
TW585774B (en) 2004-05-01
BR9707694A (pt) 1999-07-27
DE59711873D1 (de) 2004-09-30
HRP970100B1 (en) 2001-04-30
ID16038A (id) 1997-08-28
PT881906E (pt) 2004-10-29
CA2243559A1 (en) 1997-08-28
HUP9901186A3 (en) 2001-01-29
JP4184433B2 (ja) 2008-11-19
CZ268998A3 (cs) 1999-07-14
DK0881906T3 (da) 2004-12-20
IL125361A0 (en) 1999-03-12
NO983850L (no) 1998-10-21
KR19990082601A (ko) 1999-11-25
SK114598A3 (en) 1999-06-11
RO119344B1 (ro) 2004-08-30
EP0881906B1 (de) 2004-08-25
US7105162B1 (en) 2006-09-12
ES2225951T3 (es) 2005-03-16
PE55398A1 (es) 1998-09-22
ES2225951T5 (es) 2009-06-15
SK284582B6 (sk) 2005-07-01
WO1997030721A1 (de) 1997-08-28
HRP970100A2 (en) 1998-04-30
CZ295396B6 (cs) 2005-08-17
IL125361A (en) 2002-08-14
CN1211926A (zh) 1999-03-24
BG102714A (en) 1999-06-30
KR100457647B1 (ko) 2005-06-20
NZ332020A (en) 2000-02-28
PL189413B1 (pl) 2005-08-31
CA2243559C (en) 2011-08-09
TR199801649T2 (xx) 1998-12-21
CN1177610C (zh) 2004-12-01
EE9800255A (et) 1999-02-15
DK0881906T4 (da) 2009-05-25
MY119276A (en) 2005-04-30
BG63682B1 (bg) 2002-09-30
EP0881906A1 (de) 1998-12-09
PL328455A1 (en) 1999-02-01
SI0881906T2 (sl) 2009-06-30
NO983850D0 (no) 1998-08-21
ATE274350T1 (de) 2004-09-15
RS50101B (sr) 2009-01-22
HK1017257A1 (en) 1999-11-19
AU1875997A (en) 1997-09-10
SI0881906T1 (en) 2004-12-31
AU722264B2 (en) 2000-07-27
EE04481B1 (et) 2005-06-15
HUP9901186A2 (hu) 1999-07-28
YU6297A (sh) 1999-09-27
JP2000506125A (ja) 2000-05-23
HU224410B1 (hu) 2005-08-29
CO4600681A1 (es) 1998-05-08
EP0881906B2 (de) 2009-02-04

Similar Documents

Publication Publication Date Title
AR005945A1 (es) Composicion farmaceutica para la modulacion inmunitaria
ES2059565T3 (es) Virus mva de la vacuna, recombinante.
NO20015073D0 (no) Vaksiner
PT1104306E (pt) Composicoes de cpg e adjuvantes de saponina e seus metodos
CO5070674A1 (es) Vacunas con un oligonucleotido cpg como adyuvante
ATE272410T1 (de) Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
ATE516299T1 (de) Chlamydia-antigene
DK1113816T3 (da) Influenzavirus-vaccinesammensætning
NO20020348L (no) Peptid acceptor ligeringsmetoder
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
DE60144240D1 (de) Zusammensetzung mit immunogenen mikroteilchen
ES2196374T3 (es) Conjugados utiles en el tratamiento del cancer de prostata.
ES2151506T3 (es) Moleculas de adn recombinante que codifican enzimas aminopeptidasa y su uso en la preparacion de vacunas contra infecciones por helmintos.
ES2123558T3 (es) Antigenos peptidicos del vhc y procedimiento para la determinacion del vhc.
AR004341A1 (es) Vacunas contra tumores y procedimiento para su produccion.
ATE511855T1 (de) Adjuvansformulierung zur scheimhaut-applikation
ES8207429A1 (es) Un procedimiento para la preparacion de un polisacarido antigenico.
ATE424217T1 (de) Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
ATE321853T1 (de) Humanische pellino-polypeptide
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
ES2056833T3 (es) Sondas de papilomavirus y procedimiento de diagnostico in vitro de infecciones por papilomavirus.
CO5300406A1 (es) Vacuna
EE200200157A (et) Vaktsiin
ECSP972036A (es) Composicion farmaceutica para la modulacion inmunitaria
GB9818133D0 (en) Vaccine

Legal Events

Date Code Title Description
FG Grant, registration